Oric Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2020 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Oric Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2020 to Q3 2024.
  • Oric Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 9.27 %, a 11.6% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 9.27 -1.21 -11.6% Sep 30, 2024
Q2 2024 9.39 -1.05 -10.1% Jun 30, 2024
Q1 2024 9.35 -1.44 -13.3% Mar 31, 2024
Q4 2023 10.8 +0.77 +7.69% Dec 31, 2023
Q3 2023 10.5 +0.9 +9.4% Sep 30, 2023
Q2 2023 10.4 +1.61 +18.2% Jun 30, 2023
Q1 2023 10.8 +3.34 +44.8% Mar 31, 2023
Q4 2022 10 +3.99 +66.3% Dec 31, 2022
Q3 2022 9.58 +5.13 +115% Sep 30, 2022
Q2 2022 8.83 +5.43 +160% Jun 30, 2022
Q1 2022 7.45 +4.21 +130% Mar 31, 2022
Q4 2021 6.01 +1.08 +21.9% Dec 31, 2021
Q3 2021 4.45 -8.68 -66.1% Sep 30, 2021
Q2 2021 3.4 Jun 30, 2021
Q1 2021 3.24 Mar 31, 2021
Q4 2020 4.94 Dec 31, 2020
Q3 2020 13.1 Sep 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.